YNYann Nadjar

Yann Nadjar

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Yann Nadjar has a total of 430 co-authors. Here are the top co-authors by number of shared publications:

  • Foudil Lamari

    Filière Maladies Héréditaires du Métabolisme (G2M) France

    8 shared publications
  • Daniele Mandia

    Department of Neurology, Neurometabolism Unit, Reference Center for Metabolic and Lysosomal Neurological Diseases, Hôpital Pitié-Salpêtrière, Paris, France

    5 shared publications
  • Fanny Mochel

    Reference Center for Adult Neurometabolic Diseases and Leukodystrophies, Department of Medical Genetics of APHP, Sorbonne University, Paris Brain Institute (ICM), La Pitié-Salpêtrière University Hospital

    5 shared publications
  • Magali Pettazzoni

    Biochemistry and Molecular Biology Department Hospices Civils de Lyon Bron France

    5 shared publications
  • Manuel Schiff

    Reference Center for Mitochondrial Disorders (CARAMMEL) and Reference Center for Inborn Errors of Metabolism, Department of Pediatrics, Necker‐Enfants‐Malades Hospital, Assistance Publique‐Hôpitaux de Paris, University of Paris‐Cité, MetabERN Paris France

    5 shared publications
  • Bénédicte Héron

    Filière Maladies Héréditaires du Métabolisme (G2M) France

    4 shared publications

Latest Publications

  • Open Access

    Vitamin‐Responsive Disorders: From Molecular Basis to Clinical Presentation and Therapy

    by Cécile Acquaviva, Yann Nadjar, Manuel Schiff, Christine Vianey‐Saban, Alain Fouilhoux, Jean‐François Benoist

    Vitamin‐dependent cofactors are essential for numerous metabolic reactions, and defects affecting their uptake, conversion, utilisation, or regeneration constitute a heterogeneous group of inherited metabolic disorders (IMDs). Although dietary vitamin intake is sufficient to sustain coenzyme synthesis in healthy individuals, it is insufficient in vitamin‐responsive IMDs, where pharmacological supplementation can restore deficient metabolic fluxes or stabilise impaired enzymes. This review provides an integrated overview of the biochemical pathways that convert vitamins into their active coenzymes and documents all currently known hereditary disorders responsive to vitamin or coenzyme therapy, along with recommended doses. For each vitamin group (B 1 , B 2 , B 3 , B 6 , B 8 , B 9 , and B 12 ) and BH 4 , we outline absorption, intracellular trafficking, coenzyme formation and turnover, major clinical phenotypes, diagnostic biomarkers, and vitamin therapeutic considerations, including dose ranges, formulation constraints, and safety issues. The expected therapeutic benefit is graded to assist with clinical decision‐making. As many conditions are rare and have only recently been described, the evidence is sometimes limited; therefore, systematic reporting of individual responses, including vitamin forms and dosing, remains essential. Early recognition of vitamin‐responsive IMDs is critical, as timely treatment can dramatically alter disease trajectories and, in some cases, fully reverse symptoms.


  • Open Access

    Sertraline Treatment Can Mimic Niemann‐Pick Type C Biomarker Profile: A Diagnostic Pitfall

    by Maria Makrygianni, Cecile Pagan, Antony Citterio‐Quentin, Isabelle Rouvet, Giulia Dingeo, Cyril Hanin, Claudine Laurent‐Levinson, Samia Pichard, Bénédicte Héron, Clément Gourguechon, et al.

    Background: Oxysterols (cholestane‐3β,5α,6β‐triol and 7‐ketocholesterol) and N‐palmitoyl‐O‐phosphocholineserine (PPCS) are sensitive biomarkers for Niemann‐Pick disease type C (NPC) screening. However, false‐positive results occur, with a biomarker profile suggestive of NPC despite the absence of pathogenic variants in genes involved in NPC or other inborn errors of metabolism. Objective: To identify causes of false‐positive biomarker profiles mimicking NPC. Methods: We conducted a multicenter retrospective study of 15 patients with false‐positive oxysterols and PPCS profiles referred between 2017 and 2022 to two French NPC reference laboratories. Clinical data were collected via standardized chart review. The impact of Sertraline on NPC‐like biological features was evaluated using the filipin test in fibroblasts and biomarker analysis in sertraline‐treated patients. Results: Thirteen of 15 patients with false‐positive biomarkers were treated with sertraline. Two patients who discontinued sertraline showed normalization of biomarkers. The filipin test revealed that Sertraline disrupts intracellular cholesterol trafficking, a hallmark of NPC cellular features. Finally, among 47 sertraline‐treated patients without NPC‐suspicion, 26 (55%) had biomarker profile mimicking NPC. Interpretation: Sertraline use is frequently associated with elevated biomarkers that mimic NPC, representing a primary cause of false‐positive results in NPC screening. Genetic analysis of NPC1 and NPC2 remains essential to confirm NPC diagnosis. Most sertraline‐treated patients with false‐positive biomarkers presented predominantly atypical psychiatric symptoms, though one exhibited a clinical picture highly suggestive of NPC following prolonged sertraline exposure. The long‐term clinical effects of sertraline use need further evaluation.

  • Top Cited Papers
    Open Access

    2025 Consensus Clinical Management Guidelines for Niemann‐Pick Disease Type C

    by Tarekegn Hiwot, Forbes D. Porter, Tatiana Bremova‐Ertl, Uma Ramaswami, Caroline Hastings, Bénédicte Héron, Justin Hopkin, Joella Melville, Hernan Amartino, Mireia del Toro, et al.

    In 2018, the International Niemann‐Pick Disease Alliance (INPDA) and the International Niemann‐Pick Disease Registry (INPDR) developed and published comprehensive clinical management guidelines to support inclusive and standardized care pathways in Niemann‐Pick disease type C (NPC)—an ultra‐rare, autosomal recessive, neurovisceral lysosomal disorder. Since then, advances in diagnostics, care, and the approval of two novel disease‐modifying agents have underscored the need to revise these guidelines to ensure safe, consistent, and high‐quality care for those affected by NPC. In response, the INPDA and INPDR convened a multidisciplinary Guidelines Development Group (GDG) comprising individuals with NPC expertise from 14 countries across five continents, representing a broad range of specialties, as well as patients and families involved in NPC care. Informed by a comprehensive literature review and two meetings, the GDG systematically reviewed, revised, and updated the 2018 guideline statements, re‐evaluating the level of evidence, strength of recommendations, and expert agreement for each. The resulting 2025 consensus clinical management guidelines constitute a timely, up‐to‐date, and internationally applicable resource for the diagnosis, treatment, and holistic management of individuals with NPC. These guidelines serve as a critical resource for specialist centers, hospital‐based medical teams, staff involved in NPC patient care, family physicians and other primary caregivers, and, importantly, patients and their families.


  • Susd2 et Susd4 sont deux nouveaux gènes codant pour des protéines avec domaines CCP (Complement Control Protein) jouant un rôle dans plusieurs étapes du développement des circuits neuronaux au sein de cultures d'hippocampe de rat

    by Yann Nadjar

    Le développement cérébral est une succession d'étapes aboutissant à l'établissement d'un réseau neuronal. Il fait intervenir de nombreuses molécules comme des protéines d'adhésion permettant l'interaction des neurones avec leur environnement. L'implication de nombreux gènes codant des protéines d'adhésion dans la physiopathologie de maladies neuropsychiatriques comme l'autisme souligne l'intérêt à en identifier de nouveaux. Pendant ma thèse, j'ai pu caractériser deux nouveaux gènes, Susd2 et Susd4, codant des protéines contenant des domaines CCP (Complement Control Protein), classiquement connus pour leur présence dans les protéines participant à la régulation du système du Complément. Récemment, des protéines à domaines CCP ont été décrites chez la souris comme ayant une fonction dans le développement neuronal. L'existence de nombreuses protéines prédites à domaines CCP sans fonction connue m'ont conduit à tenter de caractériser Susd2 et Susd4 qui en font partie.Susd2 est exprimé dans les neurones au sein de cultures de cellules d'hippocampe de rat. Son expression atteint un pic à un stade post natal précoce, suggérant une fonction développementale. La protéine Susd2 recombinante a une localisation neuronale diffuse, mais est particulièrement enrichie dans les synapses excitatrices. La diminution de l'expression de Susd2 a pour conséquences un défaut de croissance axonale, une augmentation de la croissance dendritique, et une inhibition spécifique de la synaptogénèse excitatrice. Susd4 est également exprimé dans les neurones, avec un pic d'expression au stade embryonnaire, et semble jouer un rôle de régulation du développement dendritique.

  • Open Access

    Histogenetic Classification Predicts Outcomes in 130 Adults With Chronic Intestinal Pseudo-Obstruction

    by Minh-Chau Ta, Dominique Cazals-Hatem, Lore Billiauws, Aurélien Amiot, Marc Bellaiche, Dominique Berrebi, Benoit Coffin, Olivier Corcos, Emmanuelle Ecochard-Dugelay, Olivier Goulet, et al.

    INTRODUCTION: Chronic intestinal pseudo-obstruction (CIPO) is a rare, heterogeneous disorder associated with severe morbidity. Genetic variants and histopathological lesions have been described, but their combined evaluation has rarely been assessed in adult CIPO cohorts. This study aimed to evaluate the contribution of integrated genetic and histological analyses in adults with CIPO. METHODS: We conducted a retrospective observational study of adults with CIPO followed at a national tertiary referral center. Patients with CIPO underwent genomic profiling, including next-generation sequencing (NGS) panel, long-range polymerase chain reaction (PCR), whole-exome, and whole-genome sequencing. Centralized histological analysis of full-thickness bowel biopsies and resections was integrated with genomic data to assess their combined impact on disease outcomes. RESULTS: The cohort included 130 patients (75 females, 55 males, aged 19–74 years), followed for up to 64 years. Genetic and histological analyses characterized 82% of the patients (genetic diagnosis: n = 65/112, 58%; histological diagnosis: n = 73/96, 76%), allowing the classification of patients into 6 groups: monogenic myopathy (n = 42), mitochondriopathy (n = 19), unspecified myopathy (n = 26), autoimmune myopathy (n = 8), neuropathy (n = 9), and others (n = 26). Survival and postoperative outcomes differed across groups. In this cohort, patients with monogenic myopathy had the most favorable long-term survival (adjusted hazard ratio: 0.06, 95% CI: 0.01–0.42; P = 0.004) and higher rates of improvement after bowel resection compared with other patients. DISCUSSION: Integrated genetic and histological evaluation informed etiological classification in adults with CIPO and may aid clinical decision-making.


  • Open Access

    Increased intervals in enzyme replacement therapy for stable type 1 Gaucher disease: A non‐inferiority sequential trial emulation

    by Maxime Beydon, Jérôme Stirnemann, Karima Yousfi, Samira Zebiche, Dalil Hamroun, Anaïs Brassier, Samia Pichard, Laure Swiader, Thierry Billette de Villemeur, Bénédicte Héron, et al.

    Objective: To compare the efficacy and safety of extended interval (Q3–4W) enzyme replacement therapy (ERT) versus standard biweekly (Q2W) ERT in clinically stable type 1 Gaucher disease (GD) patients. Methods: We emulated a target trial with a sequential trial design, using data from the French Gaucher Disease Registry. Eligible patients were treated for ≥2 years biweekly without clinical events. Every 3 months, switchers to Q3–4W were matched to Q2W patients by age, sex, referral center follow‐up, disease history (bone events, anemia, thrombocytopenia, splenectomy, and hepatosplenomegaly), and dose of ERT. The primary outcome was a composite of GD‐related events (bone events, anemia, and thrombocytopenia). A 10% non‐inferiority margin was prespecified. Secondary outcomes were biomarker changes and economic analyses. Results: Among 280 eligible GD patients, 63 switched to Q3–4W and were matched to a total of 215 Q2W patients, followed for an average of 6.3 years. No significant difference in the risk of clinical events was observed between groups (hazard ratio: 0.98 [95% confidence intervals (CI): 0.54–1.51]). During follow‐up, absolute risk difference remained below the 10% non‐inferiority threshold at all timepoints. Biomarkers remained stable or slightly decreased in the Q3–4W group. The dosing interval extension led to an average reduction of 55 infusions per patient, corresponding to approximately €450,000 saved per patient over 6 years. Conclusion: In stable GD1 patients, extending ERT administration to every 3–4 weeks was non‐inferior to the standard biweekly regimen, supporting personalized spacing strategies that may improve quality of life and reduce healthcare costs.


  • Open Access

    Expert‐Designed Fact Sheets and AI ‐Based Analysis of Patient Symptoms to Combat Diagnostic Delays in Inherited Metabolic Diseases

    by Aline Cano, Xiaoyi Chen, Azza Khemiri, Anais Brassier, Arnoux Jean‐Baptiste, Roseline Froissart, Juliette Bouchereau, Célia Hoebeke, Karin Mazodier, Bénédicte Héron, et al.

    The importance of early diagnosis of inherited metabolic diseases (IMDs) is well known, as it allows early intervention to prevent or reduce complications and improve prognosis, since many of these disorders are treatable. However, diagnosis can still be delayed, and many patients remain undiagnosed. Reducing diagnosis delays is a primary goal of the French Ministry of Health and Prevention (Rare Disease Department). This article describes a national initiative coordinated by the French network for IMD, “Filière G2m.” Sixty‐seven IMD experts from various reference and competence centers in France drafted one‐page summaries dedicated to specific diseases or groups of diseases in the field of IMDs, covering the full spectrum of IMDs. These documents include keywords summarizing clinical signs which, when considered alongside data from routine biological or imaging tests, should suggest the diagnosis of an IMD. A total of 48 summaries have been drafted and are available on the Filière G2m website. To assess the accuracy and relevance of the diagnostic fact sheets, we selected 4 IMDs and compared their content with the clinical profiles of patients followed at Necker—Enfants Malades Hospital, using Natural Language Processing tools to automatically extract patient phenotypes from medical records (Dr Warehouse). We found a strong alignment between the fact sheets and the real‐world clinical data from these patients. This tool will enable patients to recognize themselves in an IMD. General practitioners will use these documents alongside diagnostic aid software. It may also support new artificial intelligence‐based technologies to identify undiagnosed patients in hospital databases.

  • MRPS Genes Causing Leukoencephalopathy With Profound Cerebral Folate Deficiency in Adults

    by Daniele Mandia, Metodi D. Metodiev, Jean‐François Benoist, Pauline Gaignard, Benedetta Ruzzenente, Stephan Zuchner, Danique Beijer, Gorka Fernandez‐Eulate, Agnès Rötig, Foudil Lamari, et al.

    MRPS genes, which encode components of the small mitoribosomal subunit, have not been previously linked to adult‐onset neurological diseases. These genes play a critical role in mitochondrial translation and the biogenesis of the oxidative phosphorylation system. Whole Genome Sequencing was performed on adult patients presenting with an unexplained neurological picture. In parallel, functional studies were carried out in patient‐derived fibroblasts to assess mitochondrial translation and the status of oxidative phosphorylation pathways. Bi‐allelic pathogenic variants in MRPS22 , MRPS23 , and MRPS34 were identified in four patients from unrelated families. All patients presented a similar complex neurological phenotype, including cerebellar ataxia, distal motor neuropathy, pyramidal syndrome, and a distinctive leukoencephalopathy on brain MRI. Additional findings included elevated cerebrospinal fluid (CSF) protein levels and profound cerebral folate deficiency. Functional analyses revealed impaired mitochondrial translation and multiple defects in oxidative phosphorylation. Treatment with oral folinic acid resulted in clinical stabilization, radiological improvement, and normalization of CSF 5‐methyltetrahydrofolate levels. Our findings expand the spectrum of mitochondrial diseases caused by defects in mitoribosomal proteins, highlighting their role in adult‐onset neurological disorders with distinctive brain imaging features, high CSF protein levels, and cerebral folate deficiency.